Healthcare and Diagnostics Growth
Lord’s Mark Industries Limited is expanding its healthcare, diagnostics and oncology businesses and targets revenue of at least ₹1,550 crore in FY2027, with a projected Profit After Tax (PAT) of ₹178 crore.
The company expects in-vitro diagnostics and renewable energy to drive near-term growth, while its sickle cell testing business and medical device platforms are expected to contribute from FY2028.
Expansion into CAR-T Therapy
The company plans to introduce CAR-T cell therapy in India through an exclusive partnership with a global manufacturer. The therapy will initially be offered at five centres, with Mumbai and Bengaluru expected to launch by March 2027.
The initiative aims to improve access to advanced cancer treatment while reducing treatment costs.
Oncology and Dialysis Network
Lord’s Mark also plans to develop an oncology hospital network in tier-2 cities through Lords Mark Medicure Limited. It will initially establish 70-bed hospitals in Vapi and Solapur and plans to raise ₹200 crore in debt financing.
Additionally, the company aims to establish 50 dialysis centres across India by March 2027, using its RENALOS dialysis machines.
International Diagnostics Expansion
Meanwhile, the company is strengthening its international diagnostics operations through subsidiaries in the UK and Switzerland. These entities will support pathology laboratory operations and distribution of diagnostic products in European markets.
As per Hindustan Times, the company has also applied for NHS approval to support its expansion into the UK healthcare market.
Genomics and Medical Devices
The company has completed patient trials for its OneDNA genomic testing platform following ICMR approval. Its Biomescan Analytics Platform has also received a manufacturing licence under India’s Medical Devices Rules, 2017.
Together, these initiatives are aimed at strengthening Lord’s Mark’s diagnostics and medical technology portfolio while expanding access to advanced healthcare services.